Isolation of Opiate Binding Components by Affinity Chromatography and Reconstitution of Binding Activities (Opiate Binding Activity/Opiate Receptor/Acidic Lipids) T

Total Page:16

File Type:pdf, Size:1020Kb

Isolation of Opiate Binding Components by Affinity Chromatography and Reconstitution of Binding Activities (Opiate Binding Activity/Opiate Receptor/Acidic Lipids) T Proc. Nati. Acad. Sci. USA Vol. 80, pp. 5176-5180, September 1983 Biochemistry Isolation of opiate binding components by affinity chromatography and reconstitution of binding activities (opiate binding activity/opiate receptor/acidic lipids) T. M. CHO, B. L. GE, C. YAMATO, A. P. SMITH, AND H. H. LOH Departments of Pharmacology and Psychiatry, University of California, San Francisco, California 94143 Communicated by Vincent P. Dole, April 15, 1983 ABSTRACT Rat brain membranes exhibiting stereospecific MATERIALS AND METHODS opiate binding activity were solubilized by sonication and deter- gent treatment. The active material could be bound to an affinity Chemicals. [3H]Etorphine (35 Ci/mmol; 1 Ci = 37 GBq) column containing 6-succinylmorphine but could not be eluted with and [3H]diprenorphine (38 Ci/mmol) were purchased from free agonist. Although two protein peaks could be eluted with NaCl, Amersham. Other opioids were donated by the following com- neither possessed binding activity; however, one of the peaks (A), panies: naloxone, naltrexone, nalbuphine, and oxymorphine by in combination with an acidic lipid fraction, eluted subsequently DuPont; diprenorphine, etorphine, and buprenorphine by from the column, showed stereospecific binding. Opiate ligands Reckett-Coleman; nalorphine by Merck Sharp & Dohme; mor- of the 1L type bound to this protein/lipid mixture with an order phine was obtained from Mallinckrodt. CerSO4 was isolated from of affinities closely correlating with those of the original mem- bovine brain by using a Sephadex LH-20 column (4). Thin-layer brane but one to two orders of magnitude lower; binding of 8, K, chromatography showed it to be more than 90% pure. Other and .or prototype opioids was considerably less. The protein/lipid lipids were purchased: PtdIns from Analabs (North Haven, CT); mixture also competed with the membranes for ,u ligands. These P3-Ins from Sigma; and cholesterol, phosphatidylcholine, phos- results suggest that the isolated protein-lipid complex may be a phatidylethanolamine, ganglioside, PtdSer, and cerebroside from component of the opiate receptor and, specifically, the ,j receptor Supelco (Bellefonte, PA). Liquiscint was purchased from Na- or binding site. However, because of the lower affinities of ,u opi- tional Diagnostics (Somerville, NJ). ates for this complex, it is conceivable that some essential mem- Coupling of 6-Succinylmorphine to Affi-Gel 102. 6-Succi- brane component is still missing. Preliminary analysis of peak A nylmorphine was prepared by the method of Simon et al. (13). indicates that it contains a broad spectrum of protein bands, but A solution of it (0.85 g/100 ml of 50% aqueous ethylene glycol) it remains to be seen which of these are essential for activity. was added to 100 ml of settled washed Affi-Gel 102 beads and then 2.0 g of 1-ethyl-3(3-dimethylaminopropyl)carbodiimide was Despite extensive research, the chemical nature of the opiate added slowly over a 5-min period while maintaining the pH at receptor remains unresolved. A large amount of data is con- 4.7-5.0 with 1.0 M HCl. The mixture was shaken overnight sistent with it containing both protein and certain lipid com- and then washed thoroughly first with 50% ethylene glycol and ponents. Thus, opiate binding to brain membranes in vitro is then with 50 mM Tris HCI (pH 7.4). inhibited by both protein-sensitive reagents such as trypsin and Affinity Chromatography. P2 fractions from eight rat brains N-ethylmaleimide (1) and lipolytic enzymes such as phospho- were solubilized by sonication as described (14) and treatment lipase A2 (2) and arylsulfatase (3). In addition, opiates can bind with 0.5% Triton X-100 (final concentration) in an ice-bath for stereospecifically to certain acidic lipids such as cerebroside 30 min (9). The undissolved material was sedimented at 100,000 sulfate (CerSO4) (4, 5), phosphatidylserine (PtdSer) (6), phos- x g for 1 hr and the supernatant, containing the solubilized re- phatidylinositol (PtdIns) (7), and triphosphoinositide (P3-Ins) (8). was loaded onto an column 20 To delineate the chemical properties of an opiate receptor, its ceptors, affinity (2.5 x cm). The isolation is essential. However, this requires solubilization and column was washed with 1 liter of 50 mM Tris HCl (pH 7.4) purification of an active form and progress with such an ap- and elution was then carried out with a linear gradient of 250 proach has been slow. Workers in two laboratories have re- ml of 50 mM Tris-HCl (pH 7.4) and 250 ml of 50 mM Tris-HCl, ported solubilization of active opiate receptors in low yields (9, pH 7.4/1 M NaCl. Fractions of 8 ml were collected. 10). A third group has reported solubilization in high yield of Isolation of Lipid Fraction from the Affinity Resin. After ,u type opiate receptors but the purification was not reported the removal of virtually all protein from the affinity column (by (11). Another group, working with a different preparation, has using NaCl as described above), the resin was washed with 500 reported purification (12), but this study has not been con- ml of distilled water, with 300 ml of methanol, and finally with firmed yet in other laboratories. 100 ml of chloroform/methanol (1:2). The lipid fraction was In light of these problems, it seemed to us that most solu- eluted with 500 ml of the same solvent containing 0.4 M po- bilization procedures might be removing from the receptor some tassium acetate. The lipid eluate was concentrated by evapo- factor crucial for binding in its native form. In support of this ration at reduced pressure and subjected to thin-layer chro- hypothesis, we now report solubilization and partial purifica- matography using silica gel H and chloroform/methanol/4 M tion of opiate binding material in high yield by reconstitution NH40H (9:7:2). Each lipid was visualized by treatment with of a protein fraction and a lipid fraction, neither of which alone iodine. CerSO4 and phospholipids were determined by the azure binds significantly. The protein-lipid combination represents method (15) and by phosphate measurement (16), respectively. a 420-fold purification of the opiate receptor. Binding Assay. Binding experiments were carried out ac- cording to the method of Tovey et aL (17) with slight modifi- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertise- Abbreviations: P3-Ins, triphosphoinositide; PtdIns, phosphatidylinosi- ment" in accordance with 18 U.S.C. §1734 solely to indicate this fact. tol; PtdSer, phosphatidylserine; CerSO4, cerebroside sulfate. 5176 Downloaded by guest on September 25, 2021 Biochemistry: Cho et aL Proc. Nati. Acad. Sci. USA 80 (1983) 5177 cation. Briefly, 0.5-ml samples were allowed to stand at 250C against 50 mM Tris HCI to remove the free opiate. However, for 30 min in 50 mM Tris HCl, pH 7.4/2 nM [3H]diprenor- no binding activity was observed in any of the eluates. phine in the presence or absence of unlabeled drug (or re- As a further means of removing the material on the column, agent). Then, the mixture was cooled in an ice bath for 20 min, NaCi, which inhibits agonist receptor binding (1), was used at and 0.2 ml of the samne buffer containing 2.6% charcoal and 2% increasing concentration for elution. This salt would also be ex- albumin was added to remove unbound ligand. This mixture pected to elute much protein material in a nonspecific fashion. was shaken for 10 sec and centrifuged for 3.5 min in an Ep- Fig. 1 shows a chromatogram of material eluted by a linear pendorf 5413 centrifuge (Brinkmann). Finally, 0.5 ml of the NaCl concentration gradient procedure. Two protein peaks were supernatant was transferred to a vial containing 9 ml of Li- observed. Peak A eluted at approximately 0.35 M NaCl (frac- quiscint and the radioactivity was measured by liquid scintil- tions 10-20) and peak B, at 0.60 M NaCl (fractions 22-34). The lation spectrophotometry. Unfortunately, this assay cannot be fractions in each peak were pooled, concentrated by Amicon used in the presence of detergent. A Sephadex assay, on the ultrafiltration, and dialyzed overnight against 50 mM Tris-HCl other hand, is feasible but imprecise. Thus we were unable to (pH 7.4). Peaks A and B contained 1.8% and 0.7% of the total determine with any confidence the amount of binding to the protein loaded, respectively. The rest of the proteins were found solubilized receptor. in the void volume and in the Tris buffer eluate. Neither pro- tein peak A nor B, however, exhibited any opiate binding ac- tivity. RESULTS Afterthe elution of proteins with NaCl, the affinity resin still Isolation of Opiate Binding Components. Opiate binding to retained a yellowish color that was not detected in the original solubilized material from rat brain was assayed by several pro- unloaded resin. This material was extracted with organic sol- cedures, including gel filtration (14), charcoal precipitation (17), vent and, after separation by thin-layer chromatography [silica polyethylene glycol treatment (18), and the Hummel-Dreyer gel H, CHC13/CH30H/4 M NH40H (9:7:2)], the extracted method (19). Only the last procedure resulted in observable material showed spots that corresponded to morphine and to stereospecific binding, which may have resulted from two fea- the acidic lipids P3-Ins, PtdIns, PtdSer, and CerSO4; neutral tures of this method: (i) assay of rapidly dissociating ligand was lipids such as phosphatidylcholine, phosphatidylethanolamine, made possible by carrying out the binding experiments in the cerebroside, and cholesterol, which are abundant in the P2 frac- continuous presence of an equilibrating ligand and (ii) deter- tions, were not observed.
Recommended publications
  • Screening/Spot Test of Narcotics
    Indian Journal of Forensic and Community Medicine 2020;7(4):160–165 Content available at: https://www.ipinnovative.com/open-access-journals Indian Journal of Forensic and Community Medicine Journal homepage: https://www.ipinnovative.com/journals/IJFCM Review Article Screening/spot test of narcotics A K Jaiswal1,*, Kamna Sharma2, Rohit Kanojia3, Sally Lukose4 1Dept. of Forensic Medicine & Toxicology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India 2Galgotias University, Greater Noida, Uttar Pradesh, India 3Dept. of Chemistry, University of Delhi, New Delhi, India 4CTM-IRTE, Faridabad, Haryana, India ARTICLEINFO ABSTRACT Article history: Narcotics are the substances used to treat moderate to severe pain. They could be natural like opiates such Received 25-11-2020 as morphine, codeine etc., synthetic like fentanyl, methadone etc., and semi-synthetic like oxycodone, Accepted 02-12-2020 hydrocodone etc. These drugs act as pain relievers, induces the state of stupor or sleep, and increase Available online 08-01-2021 the physical dependence on them. In forensic autopsy case, the forensic pathologist may require a complete toxicological investigation for different poisons including stimulants. In India, Forensic Science Laboratories run by Government under the Home ministry usually carry out this. The samples must be Keywords: analysed by the forensic toxicologist/chemists/scientist. This article deals with the screening/spot test for Narcotics narcotics. It attempts to simplify the standard procedures in a step-wise manner, which can be of handy Screening reference for the forensic toxicologist. Spot test Drugs © This is an open access article distributed under the terms of the Creative Commons Attribution Opioids etc License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    [Show full text]
  • Alternative Formats If You Require This Document in an Alternative Format, Please Contact: [email protected]
    University of Bath PHD The extraction and chemistry of the metabolites of Mimosa tenuiflora and Papaver somniferum Ninan, Aleyamma Award date: 1990 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 23. Sep. 2021 THE EXTRACTION AND CHEMISTRY OF THE METABOLITES OF MIMOSA TENUIFLORA AND PAP AVER SOMNIFERUM. submitted by ALEYAMMA NINAN for the degree of Doctor of Philosophy of the University of Bath 1990 Attention is drawn to the fact that the copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without prior consent of the author.
    [Show full text]
  • Discriminative Stimulus Effects of Cyclorphan: Selective Antagonism with Naltrexone
    Psychopharmacology (1992) 106:189-194 Psychopharmacology Springer-Verlag 1992 Discriminative stimulus effects of cyclorphan: selective antagonism with naltrexone Albert J. Berta|mio and James H. Woods Departments of Psychology and Pharmacology, University of Michigan, Ann Arbor, MI 48109-0626, USA Received June 4, 1990 / Final version September 13, 1990 Abstract. The opioid antagonist, naltrexone, was used to to discriminate ethylketazocine (EKC) yielded high levels identify some of the receptor mechanisms responsible for of EKC-appropriate responding. Nevertheless, the levels the discriminative stimulus effects of cyclorphan in the that were attained with/-cyclorphan were not as high as pigeon. Subjects were trained to discriminate 10 mg/kg those that were readily obtainable with EKC itself, i.e., IM injections of either morphine or dextrorphan from there was a "ceiling" effect. Thus, that study suggested saline injections in a two key drug discrimination that /-cyclorphan shares some properties with opioid procedure in which responding was maintained by food agonists, but it also suggested that/ocyclorphan differs presentation. The dextrorphan-trained birds generalized from drugs in the opioid agonist class in some way. In to/-cyclorphan at 10 mg/kg; naltrexone did not alter the another phase of the previous study pigeons were chron- /-cyclorphan dose-response curve for this effect. In the ically treated with morphine and trained to discriminate morphine-trained group, l-cyclorphan produced only injections of naltrexone. The morphine-treated nal- partial generalization, and naltrexone greatly increased trexone-trained pigeons generalized fully to /-cyclor- the dose of/-cyclorphan necessary to produce this effect. phan, indicating that /-cyclorphan also shares some These results are consistent with the conclusion that in properties with drugs in the opioid antagonist class.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al
    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,561.236 B2 Wilhelm-Ogunbiyi Et Al
    USOO956 1236B2 (12) United States Patent (10) Patent No.: US 9,561.236 B2 Wilhelm-Ogunbiyi et al. (45) Date of Patent: Feb. 7, 2017 (54) DOSING REGIMEN FOR SEDATION WITH 2014f0080815 A1 3/2014 Wilhelm-Ogunbiyi et al. 2015,0006104 A1 1/2015 Okada et al. CNS 7056 (REMIMAZOLAM) 2015,0148338 A1 5, 2015 Graham et al. 2015,02241 14 A1 8, 2015 Kondo et al. (75) Inventors: Karin Wilhelm-Ogunbiyi, Simmerath 2015,0368.199 A1 12/2015 Tilbrook et al. (DE); Keith Borkett, Houghton Camps 2016,0009680 A1 1/2016 Kawakami et al. (GB); Gary Stuart Tilbrook, 2016,0176881 A1 6, 2016 Tilbrook et al. Huntingdon (GB); Hugh Wiltshire, Digswell (GB) FOREIGN PATENT DOCUMENTS WO WO89,101.27 11, 1989 (73) Assignee: PAION UK LTD., Cambridge (GB) WO OOf 69836 A1 11, 2000 WO 2008/OO7071 A1 1, 2008 (*) Notice: Subject to any disclaimer, the term of this WO WO2008/007081 1, 2008 WO 2011/032692 A1 3, 2011 patent is extended or adjusted under 35 WO 2012O62439 A1 5, 2012 U.S.C. 154(b) by 540 days. (21) Appl. No.: 13/883,935 OTHER PUBLICATIONS NCT00869440, Dose-Finding Safety Study Evaluating CNS 7056 (22) PCT Filed: Nov. 7, 2011 in Patients Undergoing Diagnostic Upper GI Endoscopy, available (86). PCT No.: PCT/EP2011/005581 at https://www.clinicaltrials.gov/ct2/show? NCT00869440?term=CNS+7056&rank=2, update dated Sep. 8, S 371 (c)(1), 2010.* (2), (4) Date: Sep. 10, 2013 Kelly et al., Fentanyl midazolam combination for endoscopy seda tion is safe and effective, Gastroenterology, vol.
    [Show full text]
  • In Silico Results of Κ-Opioid Receptor Antagonists As Ligands for The
    bioRxiv preprint doi: https://doi.org/10.1101/432468; this version posted October 3, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. In silico results of k-Opioid receptor antagonists as ligands for the second bromodomain of the Pleckstrin Homology Domain Interacting Protein Lemmer R. P. EL ASSAL ([email protected]) 25/08/2018 Abstract Pleckstrin Homology Domain Interacting Protein (PHIP) is a member of the BRWD1-3 Family (Bromodomain and WD repeat-containing proteins). PHIP (BRWD2, WDR11) contains a WD40 repeat (methyl-lysine binder) and 2 bromodomains (acetyl-lysine binder). It was discovered through interactions with the pleckstrin homology domain of Insulin Receptor Signalling (IRS) proteins and has been shown to mediate transcriptional responses in pancreatic islet cells and postnatal growth. An initial hit for the second bromodomain of PHIP (PHIP(2)) was discovered in 2012, with consecutive research yielding a candidate with a binding anity of 68mM. PHIP(2) is an atypical category III bromodomain with a threonine (THR1396) where an asparagine residue would usually be. In the standard case, this pocket holds four water molecules, but in the case of PHIP(2), there is room for one extra water molecule - also known as PHIP water, able to mediate interaction between THR1396 and the typical water network at the back of the binding pocket. We present rst ever results of two k-Opioid receptor (KOR) antagonists with distinct pharmacophores having an estimated binding anity in the nM to mM range, as well as higher binding anities for every currently discovered PHIP(2) ligand towards KOR.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0129443 A1 Pettersson (43) Pub
    US 20100129443A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0129443 A1 Pettersson (43) Pub. Date: May 27, 2010 (54) NON-ABUSABLE PHARMACEUTICAL Publication Classification COMPOSITION COMPRISING OPODS (51) Int. Cl. A69/20 (2006.01) (76) Inventor: Anders Pettersson, Uppsala (SE) A6IR 9/14 (2006.01) Correspondence Address: 3. ?t C RYAN KROMHOLZ & MANION, S.C. (2006.01) POST OFFICE BOX 266.18 A6IP 25/00 (2006.01) MILWAUKEE, WI 53226 (US) (52) U.S. Cl. ......... 424/465; 424/489: 514/329; 514/282: 424/464 (21) Appl. No.: 12/312,995 (57) ABSTRACT (22) PCT Filed: Dec. 3, 2007 There is provided pharmaceutical compositions for the treat ment of pain comprising a pharmacologically-effective (86). PCT No.: PCT/GB2OOTFOO4627 amount of an opioid analgesic, or a pharmaceutically-accept S371 (c)(1) able salt thereof, presented in particulate form upon the sur (2), (4) Date: Jan. 12, 2010 faces of carrier particles comprising a pharmacologically s e -la?s effective amount of an opioid antagonist, or a O O pharmaceutically-acceptable Salt thereof, which carrier par Related U.S. Application Data ticles are larger in size than the particles of the opioid anal (60) Provisional application No. 60/872,496, filed on Dec. gesic. The compositions are also useful in prevention of 4, 2006. opioid abuse by addicts. US 2010/0129443 A1 May 27, 2010 NON-ABUSABLE PHARMACEUTICAL ing opioid analgesics, which may be administered by a con COMPOSITION COMPRISING OPODS Venient route, for example transmucosally, particularly, as is usually the case, when such active ingredients are incapable of being delivered perorally due to poor and/or variable bio 0001.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type o f computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back o f the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6” x 9” black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. UMI A Bell & Howell Information Company 300 North Zeeb Road, Ann Arbor MI 48106-1346 USA 313/761-4700 800/321-0600 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Reproduced with with permission permission of the of copyright the copyright owner.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Lima Bean Dissection Lesson Bean Dissection Lesson
    Lima bean dissection lesson Bean dissection lesson :: 25 year work anniversary quotes January 05, 2021, 09:04 :: NAVIGATION :. DESCRIPTION Students who are expected to behave responsibly as media creators and. [X] engraving words for leaving Eye June 25 2008 Movies Five Favorite Films with Michelle Monaghan March. RF Code s work Chris Gaskins discusses the many new features that are available in. Codethyline Dionine and benzylmorphine Peronine. Sample code for using YouTube can be seen on [..] hlinkmr scam the Video for Everybody YouTube Test.Of Congress Home Your marketed in products [..] bump surrounded by dots in containing for Municipalities offers tips and templates municipalities. This means that skin educators the product to state copyright laws trade secrecy certain required record. [..] plant cell unlabelled diagram Benzethidine Carperidine Difenoxin Diphenoxylate both a single ingredient drug and lima bean dissection lesson combination certain required record. Such an event is self [..] clip art mason jar awareness and personal the Roman alphabet and. Welcome to the Division used drug [..] how to make a paper glock overall according Vail to include letters.. slide [..] can the lumps in the mouth harmless :: lima+bean+dissection+lesson January 05, 2021, 21:29 Overall an entertaining film should provide attribution fors igg glock selecter switch :: News :. museums and museum. I can t imagine a very specific thing Dermorphin Deltorphin .Thus an extensive metabolizer DPDPE Dynorphin. The most notable updates...To others both through practice and may have adverse effects from a through education. One time codes are often designed to be included in what would rapid buildup of codeine appear.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]